

AD _____

Award Number: DAMD17-02-1-0434

TITLE: Synthesis of Cryptophycin Affinity Labels and Tubulin Labeling

PRINCIPAL INVESTIGATOR: KyoungLang Yang, Ph.D.
Professor Gunda I. Georg

CONTRACTING ORGANIZATION: University Of Kansas
Lawrence, KS 66045

REPORT DATE: May 2006

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 01-05-2006		2. REPORT TYPE Annual Summary		3. DATES COVERED 1 May 2002– 30 Apr 2006	
4. TITLE AND SUBTITLE Synthesis of Cryptophycin Affinity Labels and Tubulin Labeling				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER DAMD17-02-1-0434	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) KyoungLang Yang, Ph.D. Professor Gunda I. Georg Email: k_yang@web.de				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University Of Kansas Lawrence, KS 66045				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Cryptophycins are a potent, tumor-selective class of tubulin-binding antimitotic anti-cancer agents with excellent activity against MDR cancers. In order to develop these promising compounds into useful chemotherapeutic agents, it is necessary to obtain detailed information about the binding domain of the cryptophycins on tubulin. We plan to map the cryptophycin binding site through photoaffinity labeling studies. Toward this goal, we have synthesized and studied the activity of C16 side chain azido analogues and synthesized C6 dimethyl and C10 azido analogues of cryptophycin-24, by means of inventing an improved synthetic route to achieve the synthesis of diverse analogues in a more efficient way.					
15. SUBJECT TERMS Cryptophycin, microtubules, tubulin, azido analogues					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	17	19b. TELEPHONE NUMBER (include area code)


Table of Contents

Introduction.....	4
Body.....	5
Key Research Accomplishments.....	15
Reportable Outcomes.....	15
Conclusions.....	16
References.....	16

Introduction

Cryptophycins, isolated from blue-green algae (*Nostoc* sp.), are a new and potent tumor-selective class of tubulin-binding antimitotic agents¹ that show excellent activity against MDR cancer cell lines and were exceptionally active against mammary derived tumors.^{2,3} Cryptophycin-1 (**1**, Fig. 1) is the major cytotoxin in *Nostoc* sp.^{4,5} and displays IC₅₀ values in the pM range. Of special importance is the reduced susceptibility of the cryptophycins to P-glycoprotein mediated multiple drug resistance in comparison to vinblastine, colchicine, and paclitaxel. A structurally related compound cryptophycin-24, (**2**, Fig. 1, also named arenastatin A), isolated from the Okinawan marine sponge *Dysidea arenaria*⁶ and later from *Nostoc* sp. strain GSV 224,⁷ is also a potent inhibitor of tubulin polymerization. Cryptophycins are one of the best recent lead in the search for anticancer therapies. Formal and total syntheses of the cryptophycins have been published by several groups.⁸⁻¹⁴ Also, a multitude of SAR studies of these molecules have been reported.^{2,3,15,16}

Fig. 1: Structures of cryptophycins



Although relatively little is known about the interactions of cryptophycins with tubulin, it is believed that the cryptophycins may interact in a manner different from those of other tubulin-binding antimitotic agents.¹⁷⁻¹⁹ For the development of these promising compounds into useful chemotherapeutic agents, detailed information about the binding domain of the cryptophycins is essential.²⁰ Hence, we planned to prepare analogues with affinity labels at the two aromatic rings of the cryptophycin molecule. The information obtained will be used to search for effective bioactive candidates for *in vitro* and *in vivo* testing. We have already synthesized and evaluated three C16 side chain benzophenone²¹ and azido²² analogues of cryptophycin-24. These molecules were found to be better tubulin binding agents than the parent compound cryptophycin-24. These photoaffinity analogues and are therefore candidates for photolabeling studies. A radioactive benzophenone analogue of cryptophycin-24 is now available and initial photolabeling experiments with this compound look promising.

We also developed a new synthetic method to prepare the Northern half of the molecule in seven fewer steps than reported before.

Body

According to the original statement of work proposed by Dr. Vidya Ramadas, we fulfilled the goal of the tasks 1a, 1b, 1c, 2a, 2b, 3a, 3b, and 4a, 4b, as summarized below and in Schemes 1 to 9 and Tables 1 and 2 (Part A). Tasks 5a and 5b have been initiated, and we also carried out an additional study to improve our route for the synthesis of the Northern half of the molecule in order to expedite the process of synthesis of important analogs (Part B). During the switch of the postdoctoral grant from PI Dr. Ramadas to the current PI Dr. Yang, the appointment of Dr. Yang was delayed. Therefore, we have requested and obtained a no-cost extension for this project until April 30, 2006. However, PI Dr. Yang left in November 2005 for Germany due to her husband's new job in Germany. Therefore, we report here the previous summary done in May 2005 together with the rest of the results obtained afterwards until November.


Part A. Summary of the work carried out during the first two years

Task 1. Synthesis of benzophenone derived cryptophycin-24 analogue, Month 1-12


- Make large quantities of benzophenone derived octadienoate ester
- Prepare the second important synthon, southern part of the molecule
- Couple the two main synthons and convert it to the cryptophycin-24 analogue

As shown below in Schemes 1-4, the task 1, the synthesis of the benzophenone analogue **4** of cryptophycin-24, has been completed.


Scheme 1




Scheme 2



Scheme 3



Scheme 4



Task 2. Biological testing of benzophenone analogue of cryptophycin-24, Month 9-12

- Tubulin assembly assay and cell culture assay will be performed on analogue**
- Determination of suitably active leads**

As shown in Table 1 below, the benzophenone analogue **4(β)** was twice as active as the parent compound cryptophycin-24 (**2**) in the tubulin assembly assay and was therefore selected for radioactive synthesis and tubulin labeling.

Table 1. Biological Results

Compound	Tubulin Assembly IC ₅₀ , μM^a	Cytotoxicity IC ₅₀ , nM ^b		
		MCF7	MCF7-ADR	HCT-116
1	3.7	0.003	0.013	0.027
2	15	0.13	0.164	0.285
4 (β)	7.4	0.078	70	1.1
4 (α)	>100	6.0	447	25.3

^aTubulin at 1.5 mg/mL was assembled at 37 °C for 15 min in the presence of PEM buffer, 0.5 mM GTP and 8% DMSO. Microtubules were pelleted and the protein remaining in the supernatant determined. The IC₅₀ value is the concentration that reduces the amount of pelleted protein by 50%.

^bThe IC₅₀ value is the concentration that inhibits the proliferation by 50% after 72h (MCF-7 and MCF7-ADR) or 24h (HCT-116) of cell growth.


Task 3. Synthesis of azido substituted cryptophycin-24 analogue, Month 13-24

a. Synthesis of octadienoate ester


b. Synthesis of azido derivative of cryptophycin-24

As shown below in Schemes 5-9, we completed the synthesis of three azido derivatives, **18a-c**, of cryptophycin-24.




Scheme 5






Scheme 6




Scheme 7



Scheme 8






Task 4. Biological testing of azido analogue of cryptophycin-24, Month 21-24

a. Tubulin assembly assay and cell culture assay will be performed on analogue

b. Determination of suitably active leads

As shown in Table 2, the azido analogues **18a-18c** were similar in activity in the tubulin assembly assay compared to cryptophycin (**1**) and more active than cryptophycin-24 (**2**). These compounds are therefore excellent candidates for photolabeling studies.

Table 2. Biological Results.



Compound	Tubulin Assembly IC ₅₀ , μM	Cytotoxicity IC ₅₀ , nM	
		MCF7	MCF7-ADR
1	3.7	0.003	0.013
2	15	0.13	0.164
18a	2	0.027	0.134
18b	4	not determined	
18c	4	not determined	

Task 5. Synthesis of tritiated analogues and start of labeling studies, Month 25-36

- a. Synthesis of tritiated analogues as determined by previous SAR studies on benzophenone analogue and azido analogue
- b. Incubation of photoactivatable tritiated analogues with tubulin, photoactivation and cross linking
- c. Digestion of tubulin protein and separation of peptides through various chromatographic methods, isolation of labeled peptide(s), analysis of peptides by FAB MS
- d. Analysis of data and determination of the location of cryptophycin binding.

Part B. Summary of the work from 2004 to 2005

Task 5a: Synthesis of tritiated analogues as determined by previous SAR studies on benzophenone analogue and azido analogue

We prepared additional amounts of the benzophenone analogue **4**(β) and had the compound tritiated by a commercial company. Additional amounts of compound **18a** will also be prepared for radiolabeling after we have completed the labeling studies with benzophenone analogue **4**.


Task 5b: Incubation of photoactivatable tritiated analogues with tubulin, photoactivation and cross linking

Using the tritiated benzophenone derivative **4**(β), we have initiated a tubulin photolabeling study in order to identify the cryptophycin binding site. The basic experiment is to incubate the derivative with 20 μ M tubulin in buffer and irradiate with a lamp of specific wavelength for a designated length of time. The protein is precipitated with 50% cold ethanol and washed several times with 50% ethanol. The precipitate is dissolved in 0.1 M NaOH, counted and used for protein determination. In the first experiment we tested the effectiveness of three different wavelengths in the procedure using 10 μ M analogue. Radiation was for 10 min. The moles of analogue per mole of tubulin incorporated using 254 nm, 300 nm, and 350 nm radiation was 0.44, 0.32, and 0.11, respectively. In the next experiment we varied the concentration of analogue used and found increasing amounts of incorporation as the concentration was raised from 2.5 μ M to 40 μ M. Before trying to identify the sites on the protein that are modified we have several experiments to do to ensure ourselves that what we are observing is the result of specific labeling. The continuation of tasks 5 will be carried out during the no-cost extension time for the grant.

Apart from the plans in the original proposal, we also developed an alternative, more effective scheme for the synthesis and re-synthesis of our photoaffinity labels (Scheme 10). The new method utilizes the four commercially available compounds illustrated in boxes: α -pyrone, L-leucic acid, 3-chloropivalic acid, and a D-tyrosine derivative. One of the notable feature of this route is that seven steps are reduced in

comparison with the previously reported synthetic route, as a result of the use of only two protecting groups in the entire synthetic route, namely Boc and tBu. Additionally, gem-dimethyl group at C6 is introduced for the purpose of steric hindrance against hydrolytic decomposition in physiological environment.


Scheme 10



The synthesis of **20** can be attained from commercially available α -pyrone in one continuous process in 25% overall yield (Scheme 11). This is a significant improvement over previous methods that provided the same precursor **20** in lower yields as well as in 8 to 10 steps. The aldehyde moiety in the α -pyrone was unmasked by NaOtBu, which was consecutively employed for crotylboration and the double bond isomerization into conjugation with the carbonyl group with DBU resulted in the building block **20**.²³


In order to circumvent the drawback of this method due to the high cost of the starting material, we successfully scaled up its synthesis^{24,25} (Scheme 11) in an alternative way. Both, 5,6-dihydropyran-2-one and 3,4-dihydro-2H-pyran are commercially available but the later is significantly less expensive. A known protocol exists to synthesize α -pyrone in one step from coumalic acid,²⁶ however, the equipment needed for the required decarboxylation reaction was not readily available to us.

Scheme 11




After achieving the synthesis of **20**, our plan was to attempt the subsequent Heck coupling (Scheme 12) with **28** (double bond out of conjugation) and without a protecting group. However, a mixture of all possible combination of products was observed rather than the expected **29** only. Therefore, double bond isomerization with DBU was inevitable to carry out separately to yield **20**, which was used without purification for the Heck coupling reaction to furnish 41% of the desired octadienoate ester. However, the moderate yield of these reactions led us to consider attempting the Heck coupling at a later stage.

Scheme 12




The synthesis of the southern fragment was proceeded (Scheme 13) by following the reported known methods except that the dimethylamino acid **31** (see cryptophycin-52, Fig. 1) was prepared from 3-chloropivalic acid and was utilized instead of β -alanine.

Scheme13



The coupling of the two fragments **32** and **20** was realized using a traditional Yamaguchi reaction condition where the acid **32** activated with Yamaguchi chloride was reacted with alcohol **20**, resulting in the desired ester **33** in a reasonable yield. The resultant macroamide **33** was treated with two different aryl iodides under Heck coupling conditions, respectively in 80% (R = H) and 37% (R = N₃) yields. The excessive load (6 equiv) of benziodide and the use of microwave enforced the formation of the desired product **34**. However, this condition produces diphenylation at the conjugated double bond as well. Additionally, it is very difficult to force the reaction to complete always mainly because of the well-known instability of palladium metal reagents to oxygen. The vinyl benzene **34** is exposed to dioxirane to form epoxides, where the ratio of beta and alpha isomers is seemingly 2:1 always according to the H¹ NMR. To our disappointment, Dr. Yang didn't have enough time left to purify the final compounds in mixtures for submissions and the biological activities of those compounds are not determined.

Scheme 14



Key Research Accomplishments

- Total syntheses of two analogs, where a C10-azido and a C16-substituted aromatic side chains are attached, for elucidation of the tubulin binding site and structure-activity studies.
- Photoaffinity labeling studies of tubulin are being carried out with one of the analogues in its tritiated form in collaboration with Professor Richard Himes' laboratory in the Department of Molecular Biosciences.
- Establishment of a new, alternative chemical synthesis route to provide analogues in a more efficient way.

Reportable Outcomes

- Cryptophycin Affinity Labels: Synthesis and Biological Activity of a Benzophenone Analogue of Cryptophycin-24, R. Vidya, M. J. Eggen, G. I. Georg, R. H. Himes, *Bioorg. & Med. Chem. Lett.* **2003**, 13, 757-760.
- Synthesis of Cryptophycins via *N*-Acyl-beta-Lactam Macrolactonization, R. Vidya, M. J. Eggen, S. K. Nair, G. I. Georg, R. H. Himes, *J. Org. Chem.* **2003**, 68, 9687-9693.
- Cryptophycin Affinity Labels: Synthesis and Biological Evaluation of a C10 Aryl Azido Analog of Cryptophycin-24. R. Vidya, G. I. Georg, R. H. Himes, *Poster presented, 225th ACS National Meeting*, New Orleans, LA, United States, March 23-27, 2003.

- A Parallel Synthesis Demonstration Library of tri-Substituted Indazoles Containing New Antimutagenic/Antioxidant Hits Related to Benzydamine. S. Menon, H. Vaidya, S. Pillai, R. Vidya, L. Mitscher. *Com. Chem. High. Throu. Scr.* **2003**, 6, 471-480.

Conclusions

We have achieved the total syntheses of a C16 benzophenone analogue (**4**) and three C10 azido analogues of cryptophycin-24 (**18a-c**). They were tested in a tubulin assembly assay, and for their cytotoxicity against MCF7, and MCF7-ADR breast cancer cell lines. The results showed that analogue **4** is twice as active as cryptophycin-24 in the tubulin assembly assay, twice as active as cryptophycin-24 toward MCF7, and 400 times weaker than cryptophycin-24 toward MCF7-ADR cell proliferation. Compound **18a** is seven times as active as cryptophycin-24 in the tubulin assembly assay, five times as active as cryptophycin-24 against MCF7, and as active as cryptophycin-24 against MCF7-ADR. Therefore, compounds **4** and **18a** are promising candidates to characterize the tubulin binding domain of cryptophycin by photoaffinity labeling. A radioactive analogue of benzophenone analogue **4** was prepared and was used for labeling studies. The preliminary results are promising. We are planning the continuation of these photolabeling studies with **4** and/or **18a** (in radioactive form), by digesting the tubulin protein and separating the peptides through various chromatographic methods. The isolated labeled peptide(s), will be analyzed by FAB MS and the analysis of data should determine the location of the cryptophycin binding domain. During the last year, we also significantly improved the methods for synthesizing photoaffinity analogues such as **4** and **18a** and other analogues of this family of compounds.

References:

1. Jordan, M. A.; Wilson, L. *Nat. Rev. Can.* **2004**, 4, 253-265.
2. Eggen, M.; Georg, G. I. *Med. Res. Rev.* **2002**, 22, 85-101.
3. Shih, C.; Al-Awar, R. S.; Fray, A. H.; Martinelli, M. J.; Moher, E. D.; Norman, B. H.; Patel, V. F.; Shultz, R. M.; Toth, J. E.; Varie, D. L.; Corbett, T. H.; Moore, R. E. In *Anticancer Agents: Frontiers in Cancer Chemotherapy*; Ojima, I., Vite, G. D., Altmann, K., Eds.; American Chemical Society: Washington, DC, 2001; Vol. 796, pp 171-189.
4. Schwartz, R. E.; Hirsch, C. F.; Sese, D. F.; Flor, J. E.; Chartrain, M.; Fromtling, R. E.; Harris, G. H.; Salvatore, M. J.; Liesch, J. M.; Yudin, K. *J. Ind. Microbiol.* **1990**, 5, 113-124.
5. Trimurtulu, G.; Ohtani, I.; Patterson, G. M. L.; Moore, R. E.; Corbett, T. H.; Valeriote, F. A.; Demchik, L. *J. Am. Chem. Soc.* **1994**, 116, 4729-4737.
6. Kobayashi, M.; Aoki, S.; Ohyabu, N.; Kuroso, M.; Wang, W.; Kitagawa, I. *Tetrahedron Lett.* **1994**, 35, 7969-7972.
7. Subbaraju, G. V.; Golakoti, T.; Patterson, G. M. L.; Moore, R. E. *J. Nat. Prod.* **1997**, 60, 302-305.

8. Barrow, R. A.; Hemscheidt, T.; Liang, J.; Paik, S.; Moore, R. E.; Tius, M. A. *J. Am. Chem. Soc.* **1995**, *117*, 2479-2490.
9. Kobayashi, M.; Wang, W.; Ohyabu, N.; Kurosu, M.; Kitagawa, I. *Chem. Pharm. Bull.* **1995**, *43*, 1598-1600.
10. White, J. D.; Hong, J.; Robarge, L. A. *J. Org. Chem.* **1999**, *64*, 6206-6216.
11. Eggen, M.; Mossman, C. J.; Buck, S. B.; Nair, S. K.; Bhat, L.; Ali, S. M.; Reiff, E. A.; Boge, T. C.; Georg, G. I. *J. Org. Chem.* **2000**, *65*, 7792-7799.
12. Eggen, M.; Nair, S. K.; Georg, G. I. *Org. Lett.* **2001**, *3*, 1813-1815.
13. Tius, M. A. *Tetrahedron* **2002**, *58*, 4343-4367.
14. Danner, P.; Bauer, M.; Phukan, P.; Maier, M. E. *Eur. J. Org. Chem.* **2005**, 317-325.
15. Buck, S. B.; Huff, J. K.; Himes, R. H.; Georg, G. I. *J. Med. Chem.* **2004**, *47*, 696-702.
16. Buck, S. B.; Huff, J. K.; Himes, R. H.; Georg, G. I. *J. Med. Chem.* **2004**, *47*, 3697-3699.
17. Kerksiek, K.; Mejillano, M.; Schwartz, R. E.; Georg, G. I.; Himes, R. *FEBS Lett.* **1995**, *377*, 59-61.
18. Panda, D.; Himes, R. H.; Moore, R. E.; Wilson, L.; Jordan, M. A. *Biochemistry* **1997**, *36*, 12948-12953.
19. Panda, D.; Ananthnarayan, V.; Larson, G.; Shih, C.; Jordan, M. A.; Wilson, L. *Biochemistry* **2000**, *39*, 14121-14127.
20. Mitra, A.; Sept, D. *Biochem.* **2004**, *43*, 13955-13962.
21. Vidya, R.; Eggen, M. J.; Georg, G. I.; Himes, R. H. *Bioorg. & Med. Chem. Lett.* **2003**, *13*, 757-760.
22. Tripathy, N. K.; Georg, G. I.; Himes, R. H., Unpublished results.
23. Sakai, N.; Ohfuné, Y. *Tetrahedron Lett.* **1990**, *31*, 4151-4154.
24. Chidambaram, N.; Satyanarayana, K.; Chandrasekaran, S. *Tetrahedron Lett.* **1989**, *30*, 2429-2432.
25. Nakagawa, M.; Tono-zuka, M.; Obi, M.; Kiuchi, M.; Hino, T. *Synthesis* **1974**, 510-511.
26. Zimmerman, H. E.; Grunewald, G. L.; Paufler, R. M.; Sherwin, M. A. *J. Am. Chem. Soc.* **1969**, *91*, 2330-2338.